Intrinsic Imaging Awarded Phase II Clinical Trial for Treatment of Advanced Squamous Cell Carcinoma (SCC)
Boston (MA), San Antonio (TX), March 31, 2015 - Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with advanced squamous cell carcinoma (SCC).
Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and imaging charter development, site qualification, site training and management, image transfer, blinding and processing of images acquired by computed tomography (CT) or magnetic resonance imaging (MRI). Subsequently, study treatment response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation criteria.
Intrinsic Imaging’s more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists, all with significant expertise in evaluation of many cancers and their metastases – including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal, skin and thyroid. Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related.
“Intrinsic Imaging is dedicated to applying its therapeutic and regulatory expertise throughout this clinical trial,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “Our team has significant experience and expertise in the design and management of oncology clinical trials and in the determination of drug efficacy and/or disease progression of advanced squamous cell carcinoma.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
